Hideaki Okada

Kobe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.

Journal: The Lancet. Oncology

Published: April 19, 2025

Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.

Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.

Journal: Thoracic cancer

Published: December 03, 2023

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

Journal: JTO clinical and research reports

Published: June 07, 2023

Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.

Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.

Journal: Cancer medicine

Published: August 30, 2022

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 11, 2021

Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.

Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.

Journal: International journal of hematology

Published: October 07, 2021

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.

Journal: Radiation oncology (London, England)

Published: August 24, 2021

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis.

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis.

Journal: Cancer medicine

Published: April 25, 2021

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report.

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report.

Journal: JTO clinical and research reports

Published: November 09, 2020

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.

Journal: Thoracic cancer

Published: October 11, 2020

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Journal: British journal of cancer

Published: April 29, 2017

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.

Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.

Journal: Cancer chemotherapy and pharmacology

Published: September 11, 2015

Showing 1-12 of 18

Last Updated: 09/26/2026